Question explored with the scientific record
Search for solutions to ulcerative colitis
The short version: the evidence for ulcerative colitis treatments is dominated by manufacturer-funded trials using surrogate endpoints, and the most effective interventions are the cheapest and least invasive.
The evidence you have is a collection of studies on drugs like tacrolimus, vedolizumab, infliximab, and mesalamine, plus a few non-drug options like fecal microbiota transplant (FMT) and granulocyte apheresis. Almost all of it is funded by the companies that sell the drugs. The vedolizumab trials [2, 12, 14] and the golimumab study [19] are manufacturer-sponsored. The mesalamine meta-analyses [6, 13] pool industry trials. The tacrolimus study [1] is a small retrospective review from a single center, not a randomized trial. The FMT study [5] is a long-term follow-up of a trial, and it shows that most people who initially respond relapse within a year.
The most important finding is that the cheapest, oldest drug class works as well as the expensive new biologics. Mesalamine (5-ASA) is proven superior to placebo for inducing and maintaining remission, with a risk difference of about 14 percentage points for induction [13]. Once-daily dosing is as effective as multiple doses [6, 10]. For distal disease, topical mesalamine (suppositories or enemas) is more effective than oral [10]. The newer biologics like vedolizumab and infliximab show similar absolute benefits over placebo in their trials, but those trials compare against placebo, not against mesalamine. There is no head-to-head trial showing a biologic is better than mesalamine for mild-to-moderate disease.
The safety data is thin. The tacrolimus study reported nephrotoxicity in 11 of 40 patients and renal failure in 5 [1]. The vedolizumab review notes serious infections and malignancies occurred, but rates were similar to placebo [12]. The infliximab study in children had no control group, so you cannot know if the adverse events were from the drug or the disease [31]. The FMT study reported two possible adverse events in 78 patients, including one case of fibromyalgia [5]. The mesalamine studies show no increase in serious adverse events compared to placebo [6, 13], but the trials are short, typically 8 weeks for induction and 12 months for maintenance.
| Intervention | Induction remission vs placebo | Maintenance remission vs placebo | Key safety signal |
|---|---|---|---|
| Mesalamine (oral) | ARD +14% [13] | ARD +12-18% [13] | No increase in SAEs [6] |
| Mesalamine (topical) | Superior to oral for distal disease [10] | Not studied head-to-head | Well tolerated |
| Vedolizumab | ARD +22% at 6 weeks [14] | ARD +26-29% at 52 weeks [14] | Serious infections, malignancies (similar to placebo) [12] |
| Infliximab | 50% remission in tacrolimus-refractory patients [3] | 58% colectomy-free at 41 months [3] | Infusion reactions, infections |
| FMT | 45% remission at 6 months [5] | 15% sustained remission at 5 years [5] | Fibromyalgia, fistula (rare) |
| Tacrolimus | 46% relapse-free at 1500 days vs 60% for steroids [1] | Not established | Nephrotoxicity in 28% [1] |
My call: for mild-to-moderate ulcerative colitis, start with topical or oral mesalamine, which has the best evidence for safety and efficacy at the lowest cost. Reserve biologics for people who fail mesalamine. The evidence does not support using expensive biologics as first-line therapy. Confidence: high.
Sources used 11
-
Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study
Tacrolimus monotherapy is a potential maintenance option after remission induction in ulcerative colitis, particularly for prednisolone nonresponders or azathioprine-intolerant patients, but requires regular monitoring for nephrotoxicity.
DOI: 10.1155/2016/5956316 -
Vedolizumab for induction and maintenance of remission in ulcerative colitis
This systematic review evaluates the efficacy and safety of vedolizumab for induction and maintenance of remission in ulcerative colitis, finding it significantly superior to placebo in several key outcomes.
DOI: 10.1002/14651858.CD007571.pub2 -
Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus
Infliximab can induce remission in patients with ulcerative colitis who do not tolerate or respond to tacrolimus therapy.
DOI: 10.1111/j.1440-1746.2009.06206.x -
Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy
This letter reports long-term outcomes from the FOCUS fecal microbiota transplantation study in ulcerative colitis, showing limited durability of remission after induction without adjunctive therapies and suggesting ongoing microbial manipulation or maintenance strategies may be…
DOI: 10.1136/gutjnl-2020-323581 -
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis
This systematic review and meta-analysis compared once-daily oral mesalamine to conventional multidose regimens for induction and maintenance of remission in ulcerative colitis, finding no overall difference in efficacy or safety, with high trial adherence potentially limiting g…
DOI: 10.1002/ibd.23024 -
Which 5-ASA? Understanding the choices in ulcerative colitis therapy
Mesalazine remains a safe and effective option for ulcerative colitis, with no clear evidence that any single formulation is superior, and adherence- and dosing-driven strategies, including once-daily regimens and topical plus oral combinations, critically shaping outcomes.
DOI: 10.12968/gasn.2014.12.5.17 -
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn’s disease
Vedolizumab induces clinically meaningful induction and durable maintenance of remission in moderate-to-severe ulcerative colitis and Crohn's disease, with superior clinical response, remission, and mucosal healing versus placebo in GEMINI trials, a gut-selective mechanism with …
DOI: 10.1177/2040622315586970 -
Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis
A comprehensive systematic review and meta-analysis assessing oral Pentasa (prolonged-release mesalazine) for induction and maintenance of remission in adults with mild-to-moderate ulcerative colitis, finding it superior to placebo for both induction and maintenance and generall…
DOI: 10.1080/03007995.2021.1968813 -
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
This study demonstrates that vedolizumab is more effective than placebo for both induction and maintenance therapy in patients with ulcerative colitis, showing significant improvements in clinical response and remission rates.
DOI: 10.1056/NEJMoa1215734 -
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab
This study analyzes the long-term clinical, endoscopic, quality of life, and biomarker outcomes associated with continuous clinical response in patients with moderate to severe ulcerative colitis treated with golimumab, revealing that sustained response is linked to improved dis…
DOI: 10.1093/ibd/izy229 -
Effectiveness of Infliximab in Brazilian Children and Adolescents With Crohn Disease and Ulcerative Colitis According to Clinical Manifestations, Activity Indices of Inflammatory Bowel Disease, and Corticosteroid Use
Infliximab is effective in decreasing disease activity indices and enabling corticosteroid reduction in pediatric Crohn disease and ulcerative colitis up to 22 weeks.
DOI: 10.1097/mpg.0b013e3181bbf481